Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter revenue of $0
Capricor Therapeutics Inc. reported cash, cash equivalents and marketable securities of approximately $98.6 million as of September 30, 2025, down from $151.5 million at December 31, 2024. Revenues for the third quarter of 2025 were $0, compared to $2.3 million in the same period of 2024. For the first nine months of 2025, revenues were $0, compared to $11.1 million for the first nine months of 2024. Total operating expenses for the third quarter of 2025 were $26.3 million, up from $15.3 million in the third quarter of 2024. Operating expenses for the first nine months of 2025 were $79.0 million, compared to $46.0 million in the same period of 2024. During the period, Capricor advanced its HOPE-3 Phase 3 trial of Deramiocel for the treatment of Duchenne muscular dystrophy, with topline results expected in the fourth quarter of 2025 and commercial launch preparations underway for a potential 2026 market introduction. The company also continued its NIAID-sponsored Phase 1 trial of the StealthX exosome-based vaccine, with initial data expected in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-109119), on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.